Dfe Pharma
Dfe Pharma, headquartered in Germany, is a leading provider of excipients and pharmaceutical solutions, specialising in the development and manufacturing of high-quality products for the global pharmaceutical industry. Founded in 2015, the company has quickly established itself as a key player in the market, with a strong presence in Europe, North America, and Asia. Dfe Pharma's core offerings include a diverse range of excipients, such as binders, fillers, and disintegrants, which are essential for the formulation of solid dosage forms. What sets Dfe Pharma apart is its commitment to innovation and quality, ensuring that their products meet the stringent requirements of the pharmaceutical sector. With a focus on customer collaboration and tailored solutions, Dfe Pharma continues to enhance its market position, contributing to the success of its partners in the ever-evolving pharmaceutical landscape.
DitchCarbon Score
How does Dfe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dfe Pharma's score of 44 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dfe Pharma's reported carbon emissions
In 2023, DFE Pharma reported total carbon emissions of approximately 964,130,000 kg CO2e, with Scope 1 emissions at about 6,601,000 kg CO2e, Scope 2 emissions at around 5,340,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled approximately 952,189,000 kg CO2e. DFE Pharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, upstream transportation, and end-of-life treatment of sold products, also by 2030. Furthermore, DFE Pharma is committed to reducing its Scope 3 emissions related to deforestation-linked commodities by 30.3% by 2030, with a no-deforestation pledge set for completion by December 31, 2025. These targets align with industry standards and reflect DFE Pharma's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 1,440,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 630,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 9,606,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dfe Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
